A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]
To explore the efficacy of BIBW 2992 defined by the objective response rate (Complete Response, Partial Response) as determined by Response Evaluation Criteria in Solid Tumours\[RECIST\] 1.1 in the patients with advanced (stage IIIB or IV) adenocarcinoma of the lung harbouring wild-type EGFR.
Carcinoma, Non-Small-Cell Lung
DRUG: afatinib (BIBW 2992)
Percentage of Participants With Best Objective Response, Percentage of participants with best objective response: confirmed complete response (CR) or confirmed partial response (PR) according to RECIST (version 1.1)., Baseline till progression or death
Percentage of Participants With Disease Control (DC), Percentage of participants with objective response or stable disease (SD) as determined by RECIST version 1.1., Baseline till progression or death|Progression Free Survival (PFS) Time, PFS time is defined as time from start of treatment to the earliest of progression (RECIST version 1.1), clinical progression (investigator), start of new anti-cancer treatment or death, Baseline till end of study or death|Duration of Disease Control (DC), Duration of diesease control (DC) (objective response or stable disease (SD) as determined by RECIST version 1.1)., Baseline till progression or death|Time to OR, The time to objective response (OR) was the duration from the first treatment to the time when the measurement criteria for CR and/or PR were met according to RECIST 1.1 criteria., Baseline till progression or death|Duration of OR, Duration of OR was measured from the time the criteria for CR or PR (whichever was documented first) were first met until the first date that progressive disease or death was objectively documented., Baseline till progression or death
To explore the efficacy of BIBW 2992 defined by the objective response rate (Complete Response, Partial Response) as determined by Response Evaluation Criteria in Solid Tumours\[RECIST\] 1.1 in the patients with advanced (stage IIIB or IV) adenocarcinoma of the lung harbouring wild-type EGFR.